Sign up Australia
Proactive Investors - Run By Investors For Investors

SomnoMed showcases SomnoDent sleep apnea device at SLEEP 2009

SomnoMed showcases SomnoDent sleep apnea device at SLEEP 2009

Showcasing its SomnoDent™ MAS dental sleep apnea device, SomnoMed (ASX: SOM) has participated at the Annual SLEEP 2009 exhibition in Seattle.  This is the centre point for Dental Sleep Medicine and the Sleep Medicine fraternity worldwide.

SomnoDent™ MAS was featured for a record number of American Association of Dental Sleep Medicine (AADSM) practitioners, with over 600 delegates and the medical conference of Associated Professional Sleep Societies (APSS), which attracted more than 6,000 delegates.

Exhibition activities were focused on the positioning of the SomnoDent MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing. 

The SomnoDent™ MAS dental sleep device consists of two acrylic plates fitted over the upper and low teeth. A patented fin coupling mechanism on the lower arch accurately positions the lower jaw (mandible) a little forward of its natural position.

Ralf Barschow, SomnoMed's CEO said that SLEEP 2009 was a very important strategic investment for SomnoMed and "I am very pleased with the response. It offered an ideal opportunity to present the SomnoDent™ MAS therapeutic option to a broader medical fraternity."

SomnoMed is positioning the SomnoDent™ MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing.

Barschow said SLEEP 2009 "also confirmed our view that there is a significant demand for the SomnoDent MAS therapy for all patients diagnosed and untreated, as well as non-compliant to traditional treatment options, such as surgery or CPAP."



Register here to be notified of future SOM Company articles
View full SOM profile

SOMNOMED Timeline

Newswire
May 03 2016

Related Articles

AZN3.jpg
November 11 2016
Patent safeguards the technology at the heart of the device that offers a non-invasive method of monitoring diabetes.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
FatCity.jpg
January 14 2016
If everyone could be as active as the York-based outfit there would not be such a pressing demand for its products.

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.